What question did this study set out to answer?

To compare the persistence and kinetics of humoral and cellular immune responses up to eight months following various homologous and heterologous third COVID-19 vaccine doses.

April 20, 2023Journal of InfectionOpen Access

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

View Full Paper

Ask AI

Bookmark

Authors

XLXinxue LiuUniversity of Oxford AMAlasdair MunroUniversity Hospital Southampton NHS Foundation Trust AWAnnie WrightImperial College London

Discussion

Member takes

Implication

Randomized trial finds viral vector boosters after mRNA primary vaccination sustain antibodies longer than third mRNA doses in adults, suggesting optimal schedules for durable immunity.

Key Points

To compare the persistence and kinetics of humoral and cellular immune responses up to eight months following various homologous and heterologous third COVID-19 vaccine doses.
Multicentre, randomized, controlled phase 2 trial across the UK evaluating immune responses from day 28 to day 242 across seven booster arms (five full-dose, two half-dose) compared to BNT162b2.
Analyzed N=817 baseline-seronegative, SARS-CoV-2-naïve participants (median age 72 years, IQR 55–78) stratified by primary series of ChAdOx1 nCov-19 or BNT162b2.
In participants primed with BNT162b2, anti-spike IgG titers decayed more slowly following Ad26.COV2.S and ChAdOx1 boosters, with Ad26.COV2.S generating significantly higher IgG levels than BNT162b2 by 3 months post-vaccination.
In participants primed with ChAdOx1, mRNA boosters achieved the highest absolute anti-spike IgG titers at day 242, while Ad26.COV2.S displayed the slowest antibody decay rate.
Full-dose and half-dose BNT162b2 demonstrated similar decay kinetics, with geometric mean ratios between 0.76 and 0.94 across follow-up time points, while cellular immune persistence did not differ between study arms.

Cite This Study

Liu et al. (2023) studied this question.

synapsesocial.com/papers/6a97f305cc0e6ba05e76f349 https://doi.org/10.1016/j.jinf.2023.04.012

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial finds viral vector boosters after mRNA primary vaccination sustain antibodies longer than third mRNA doses in adults, suggesting optimal schedules for durable immunity.

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider